318000.KQ Korea Bio-Gen Co.Ltd
- Market cap
- KRW 20.8B
- P/E
- 13.4x
- P/B
- 0.44x
- ROE
- 2.5%
- Dividend yield
- 3.14%
- Fundamental score
- 1.8/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 318000.KQ undervalued?
Graham number318000.KQ trades 48.6% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Korea Bio-Gen Co.Ltd fundamental analysis
9 of 22 checks passedROE 0/2
Low return on equity (2.5%), below 10%.
ROA 0/1
Return on assets (2.2%) is below the industry median (4.7%).
Profit Consistency 2/2
Profitable for 6 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (-31.2%) is not above the 5-year average (-5.1% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (-31.2%) is below the industry median (-16.9%).
Revenue Growth 0/2
Revenue shrank 0.6% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 1/1
EBIT is 174.6x against interest expense, well covered.
PE vs Market 0/1
PE (13.4x) is above the market median (11.3x).
PE vs Industry 0/1
PE (13.4x) is above the industry median (9.1x).
PBV 1/1
Price to book (0.4x) is below the industry median (0.6x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 5.9, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (3.1%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 25.2%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Korea Bio-Gen Co.Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Korea Bio-Gen Co.Ltd
KBG Corp. produces and supplies a range of fine chemicals in South Korea and internationally. The company offers silicone chemicals, such as functional organosilanes, functional silicone polymers, silicone resins and intermediates, silicone pressure sensitive adhesives, and silicone materials for electronics; specialty chemicals, including polymerization inhibitors; and food additives, as well as silicon inorganic chemical materials, organic materials, bio-materials, and oth…
Full company profileKorea Bio-Gen Co.Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Korea Bio-Gen Co.Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 14.4B | 16.4B | 18.5B | 19.8B | 27.2B | 24.3B | 21.6B | 24.9B | 23.9B | 23.3B |
| Gross Profit | 4.30B | 4.87B | 5.23B | 6.08B | 9.22B | 7.36B | 7.21B | 8.00B | 7.15B | 5.56B |
| Operating Income | 2.10B | 2.87B | 2.97B | 3.41B | 5.89B | 4.11B | 4.53B | 4.02B | 2.99B | 873M |
| EBITDA | - | - | - | - | - | 5.00B | 6.59B | 5.56B | 4.64B | 2.82B |
| Net Income | 1.64B | 2.13B | -1.40B | 3.12B | 4.00B | 3.25B | 4.58B | 3.77B | 2.59B | 1.16B |
| EPS | 746 | 968 | -173 | 386 | 494 | 399 | 527 | 433 | 298 | 134 |
| Balance Sheet | ||||||||||
| Total Assets | 16.8B | 19.8B | 28.2B | 31.1B | 42.0B | 43.1B | 46.0B | 51.6B | 52.3B | 53.1B |
| Total Liabilities | 7.88B | 8.83B | 2.47B | 2.91B | 10.4B | 8.13B | 3.90B | 6.73B | 5.42B | 6.11B |
| Shareholders' Equity | 8.93B | 11.0B | 25.7B | 28.2B | 31.6B | 34.9B | 42.1B | 44.9B | 46.9B | 47.0B |
| Cash & Short-term Investments | 1.67B | 2.82B | 9.64B | 10.8B | 12.5B | 11.3B | 15.3B | 10.7B | 3.40B | 3.79B |
| Total Debt | 5.19B | 2.44B | 19.1M | 364M | - | - | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 1.38B | 1.98B | 3.05B | 2.58B | 3.09B | 1.67B | 9.47B | 4.29B | 7.34B | 3.31B |
| Capital Expenditure | 778M | 841M | 2.55B | 872M | 2.36B | 2.29B | 2.42B | 5.12B | 462M | 164M |
| Free Cash Flow | - | - | 266M | 1.71B | 734M | -618M | 7.05B | -826M | 6.88B | 3.15B |
| Ratios | ||||||||||
| ROE | 18.4% | 19.4% | -5.5% | 11.1% | 12.7% | 9.3% | 10.9% | 8.4% | 5.5% | 2.5% |
| ROA | 9.8% | 10.8% | -5.0% | 10.1% | 9.5% | 7.6% | 10.0% | 7.3% | 5.0% | 2.2% |
| Net Profit Margin | 11.4% | 13.0% | -7.6% | 15.8% | 14.7% | 13.4% | 21.2% | 15.1% | 10.8% | 5.0% |
| Debt to Equity | 0.58x | 0.22x | 0.00x | 0.01x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Korea Bio-Gen Co.Ltd dividends
- Dividend yield
- 3.14%
- Forward dividend
- 60.00 KRW
- Payout ratio
- 25.2%
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 652M | 75 | 25.2% |
| 2024 | KRW 870M | 100 | 23.1% |
| 2023 | KRW 836M | 96 | 18.2% |
| 2022 | KRW 810M | 99 | 24.9% |
| 2021 | KRW 606M | 75 | 15.1% |
| 2020 | KRW 406M | 50 | 13.0% |
| 2019 | KRW 74.4M | 9.15 | - |
| 2018 | KRW 77.0M | 35 | 3.6% |
| 2017 | KRW 165M | 75 | 10.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.005:1 on Dec 28, 2022.
Who owns Korea Bio-Gen Co.Ltd
- Insiders 36.29%
- Institutions 0.00%
- Public & others 63.71%
- Shares outstanding 8.70M
- Free float 6.27M
Korea Bio-Gen Co.Ltd company profile
- Company name
- Korea Bio-Gen Co.Ltd
- Ticker
- 318000.KQ
- ISIN
- KR7318000007
- Exchange
- KOSDAQ
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 72
- Fiscal year end
- December
- Address
- 84-19 Daeheungsindeok-Road, Cheonan-si, South Korea, 31248
- Phone
- 82 4 1523 6201
- Website
- kbgtech.co.kr
About Korea Bio-Gen Co.Ltd
KBG Corp. produces and supplies a range of fine chemicals in South Korea and internationally. The company offers silicone chemicals, such as functional organosilanes, functional silicone polymers, silicone resins and intermediates, silicone pressure sensitive adhesives, and silicone materials for electronics; specialty chemicals, including polymerization inhibitors; and food additives, as well as silicon inorganic chemical materials, organic materials, bio-materials, and others. It serves electric and electronics, automobile, construction, chemical related industries of food and pharmaceuticals, petrochemicals, etc. The company was formerly known as Korea Bio-Gen Co.,Ltd. KBG Corp. was founded in 2001 and is headquartered in Cheonan-si, South Korea.
Korea Bio-Gen Co.Ltd management
2- Samuel BooCEO & Director · born 1986
- TaeGyun BooSales Manager · born 1966